Led by Lotus Lake Capital, the financing will accelerate the development of TPM004, a differentiated ultra-long-acting amylin/calcitonin receptor dual agonist, and advance the company's proprietary PepTetris™ peptide discovery platform for obesity, diabetes, and other metabolic diseases Developing a differentiated portfolio of ultra-long-acting peptide therapeutics targeting metabolic diseases, including obesity, type 2 diabetes, and related disorders, with the potential to achieve best-in-clas

Close on the heels of a Phase III win in small-cell lung cancer (SCLC), GSK said Tuesday its Hansoh Pharmaceutical-partnered B7-H3-targeting antibody-drug conjugate (ADC) risvutatug rezetecan (ris-rez) secured another late-stage triumph, this time in osteosarcoma. The ARTEMIS-011 trial, in China, enrolled an estimated 117 patients aged 12 years and above with osteosarcoma who had progressed after at least two prior lines of systemic therapy. Participants were randomised to receive ris-rez or a

July 28, 2026 -- Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) drug discovery and development, today announced that it has successfully completed patient enrollment in its global, multi-center Phase 2 clinical trial evaluating YA-101, its flagship candidate for the treatment of Multiple System Atrophy (MSA). Top-line clinical data from the trial are expected in the first quarter of 2027. In

Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment July 28, 2026 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared th

Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy in development for Angelman syndrome, advanced into the pivotal Phase 3 BEACON clinical trial Angelman syndrome affects approximately 30,000 diagnosed individuals in the US and EU5 and has no approved treatments Topline data expected in early 2029 July 28, 2026 -- OHB Pediatrics Ltd. d/b/a Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced that the first participant has been dosed in B

Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa®), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in a Global Phase 3 Program of Hepatitis C Virus (HCV) Treatments Results Reinforce Potential Best-in-Class Pro BEM/RZR as a Short 8-Week Treatment for Patients Without Cirrhosis Up to 4 Million People in the US Living with HCV, Which Can Progress to Cirrhosis, End-Stage Liver Disease

July 28, 2026 -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced positive feedback from the U.S. Food and Drug Administration (FDA) following an End-of-Phase 1 (EOP1) meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia (AML). The EOP1 meeting focused on the planne

Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug. The prize for argenx is FB102, an anti-CD122 antibody that demonstrated success in a phase 1b study earlier this month. In that trial, Forte tied FB102 to a 29.6% improvement in a score of facial vitiligo. A readout for phase 2 celiac trial is expected later this year. Argenx, which has previously invested in Forte, said phase 1 studies of FB102 in both indications were “key driv

- Company’s third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease - July 28, 2026 -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IND application to initiate a Phase 1

The venture financing and AMED grant funding position CORE to accelerate development of novel lineage-based oncology therapies for patients around the world. July 28, 2026 -- CORE Biomedicine, a biotechnology company pioneering lineage-based precision oncology therapeutics, today announced the completion of a $21 million Series A financing. The round is co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, alongside participation from InnoPinnacle Fund, Mitsubishi UFJ Capital Co.,